An interventional study of tampon D and tampon M in Menstruation, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-26.
Sponsored by Procter and Gamble · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the impact on vaginal health of four different tampons using gynecologic assessment and subjective assessment of comfort during in-use conditions
Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: To be considered eligible for enrollment into this study subjects must meet the following criteria:
Exclusion Criteria: Subjects will be excluded from the study if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Regular absorbency tampon
Device: tampon D
Regular absorbency tampon
Device: tampon M
Regular absorbency tampon
Device: tampon T
Regular absorbency tampon
Device: tampon V
regular absorbency tampon
regular absorbency tampon
regular absorbency tampon
regular absorbency tampon
Tolerance of Tampon Wear Via Physician Assessment of Vaginal Health
The physician examiner determined tampon tolerance based on the following: 1) Vaginal erythema (0-4 scale), 2) vaginal lacerations (presence or absence), 3) vaginal abrasions (presence or absence), 4) vaginal pH, 5) vaginal discharge
Time frame: within 72 hours last tampon use
Vaginal pH
Vaginal pH
Time frame: within 72 hours last tampon use
Subject Comfort Diary
Diary assessment of tampon wear comfort. This assessment uses a 5-point scale which was summarized using the mean as the summary statistic. This questionnaire measured overall comfort using a +2 to -2 scale that was converted to a 0 to 100 scale: 100 = excellent rating and 0 =poor rating
Time frame: 4 months
Subject Comfort Questionnaire
Post-menstruation assessment of tampon wear comfort. This assessment uses a 5-point scale which was summarized using the mean as the summary statistic. This questionnaire measured overall satisfaction using a +2 to -2 scale that was converted to a 0 to 100 scale: 100 = excellent rating and 0 = poor rating
Time frame: 4 months
| Milestone | Overall Study |
|---|---|
| Started | 94 |
| Received tampon d | 91 |
| Received tampon m | 92 |
| Recived tampon t | 90 |
| Received tampon v | 91 |
| Completed | 89 |
| Not completed | 5 |
| Withdrew: Non-compliance | 1 |
| Withdrew: Lost to follow-up | 4 |
The physician examiner determined tampon tolerance based on the following: 1) Vaginal erythema (0-4 scale), 2) vaginal lacerations (presence or absence), 3) vaginal abrasions (presence or absence), 4) vaginal pH, 5) vaginal discharge
| Participants | Marketed Tampon D | Marketed Tampon M | Marketed Tampon T | Marketed Tampon V |
|---|---|---|---|---|
| Erythema score greater than 0 | 0 | 0 | 0 | 0 |
| Presence of Ulcerations | 0 | 0 | 0 | 0 |
| Presence of Abrasions | 0 | 0 | 0 | 0 |
| Abnormal Vaginal Discharge | 0 | 0 | 0 | 0 |
Vaginal pH
| pH | Marketed Tampon D | Marketed Tampon M | Marketed Tampon T | Marketed Tampon V |
|---|---|---|---|---|
| Vaginal pH | 4.43 ± 0.053 | 4.46 ± 0.061 | 4.40 ± 0.055 | 4.44 ± 0.061 |
Diary assessment of tampon wear comfort. This assessment uses a 5-point scale which was summarized using the mean as the summary statistic. This questionnaire measured overall comfort using a +2 to -2 scale that was converted to a 0 to 100 scale: 100 = excellent rating and 0 =poor rating
| units on a scale | Marketed Tampon D | Marketed Tampon M | Marketed Tampon T | Marketed Tampon V |
|---|---|---|---|---|
| Subject Comfort Diary | 81.7 ± 2.60 | 78.5 ± 2.56 | 74.0 ± 2.58 | 73.2 ± 2.57 |
Post-menstruation assessment of tampon wear comfort. This assessment uses a 5-point scale which was summarized using the mean as the summary statistic. This questionnaire measured overall satisfaction using a +2 to -2 scale that was converted to a 0 to 100 scale: 100 = excellent rating and 0 = poor rating
| units on a scale | Marketed Tampon D | Marketed Tampon M | Marketed Tampon T | Marketed Tampon V |
|---|---|---|---|---|
| Subject Comfort Questionnaire | 78.4 ± 3.17 | 71.5 ± 3.17 | 66.5 ± 3.17 | 60.9 ± 3.15 |
Collected over six months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Marketed Tampon D | 0/91 (0%) | 1/91 (1.1%) | 0/91 (0%) |
| Marketed Tampon M | 0/92 (0%) | 0/92 (0%) | 0/92 (0%) |
| Marketed Tampon T | 0/90 (0%) | 0/90 (0%) | 0/90 (0%) |
| Marketed Tampon V | 0/91 (0%) | 0/91 (0%) | 0/91 (0%) |
| Event | Marketed Tampon D | Marketed Tampon M | Marketed Tampon T | Marketed Tampon V |
|---|---|---|---|---|
| Post-traumatic stress disorderPsychiatric disorders | 1/91 | 0/92 | 0/90 | 0/91 |
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 33.4 (18 to 49) |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 94 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 92 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Overall Study |
|---|---|
| American Indian or Alaskan Native | 2 |
| Asian Indian | 0 |
| Asian Oriental | 2 |
| Black | 36 |
| Caucasian | 51 |
| Mutli-racial | 0 |
| Native Hawaiian or Pacific Islander | 0 |
| Other | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Jul 2018, 6 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.